Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 6/20 | 0.57 |
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285621 | 0.91 | P2RX4 (0.67) | P2RX4ANO1 | |
| SCHEMBL26186545 | 0.91 | P2RX4 (0.67) | P2RX4ANO1 | |
| SCHEMBL25375429 | 0.90 | P2RX4 (0.56) | P2RX4ANO1P2RX7ACKR3KCNJ5 | |
| SCHEMBL26186538 | 0.87 | P2RX4 (0.54) | P2RX4ANO1P2RX7ACKR3KCNJ5 | |
| SCHEMBL30285749 | 0.87 | P2RX4 (0.54) | P2RX4ANO1P2RX7ACKR3KCNJ5 | |
| SCHEMBL30285719 | 0.87 | P2RX4 (0.64) | P2RX4ANO1KCNJ5KCNJ3 | |
| SCHEMBL26186543 | 0.87 | P2RX4 (0.64) | P2RX4ANO1KCNJ5KCNJ3 | |
| SCHEMBL25372122 | 0.86 | P2RX4 (0.61) | P2RX4ANO1P2RX7ACKR3KCNJ5 | |
| SCHEMBL25374746 | 0.85 | P2RX4 (0.68) | P2RX4ANO1 | |
| SCHEMBL30285573 | 0.84 | P2RX4 (0.60) | P2RX4ANO1ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | claimed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | claimed |
| EP-4171744-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | claimed |
| EP-4172146-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | claimed |
| CN-115996911-A | Substituted N-phenylacetamides having P2X4 receptor antagonistic activity | 拜耳公司 | 2023-04-21 | — | — | CN | claimed |
| CN-115989218-A | Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases | 拜耳公司 | 2023-04-18 | — | — | CN | claimed |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | disclosed |
| CN-115996911-A | Substituted N-phenylacetamides having P2X4 receptor antagonistic activity | 拜耳公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115989218-A | Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases | 拜耳公司 | 2023-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | P2RX2, P2RX5, P2RX3 | P2RX4 4/4885ANO1 964/4885P2RX7 6/4885 |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | P2RX2, P2RX4, P2RX5 | P2RX4 2/4885ANO1 3464/4885P2RX7 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.